Released Jan 29, 2018, after the close
10-K filed Jan 29, 2018, 90 days after period end · 0001654954-18-000819
Q4 2017 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$547.03K-$547.03K derivedN/M vs Q4 2016N/M vs Q3 2017
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$840,679−21.8%
Operating Incomederived$125,001N/M
Operating Cash Flowderived$279,565−39.6%
Free Cash Flowderived$587,239N/M
What the release said
The release
Same quarter
| Metric | Q4 2017dderived from reported figures | Q4 2016dderived from reported figures | Q4 2015dderived from reported figures | Q4 2014dderived from reported figures |
|---|---|---|---|---|
| Net Income | -$547.03K | -$513.32K | $523.45K | $826.87K |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pharma-Bio Serv, Inc. · CIK 1304161 · Engraved from SEC EDGAR